Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down – Should You Sell?

Shares of Novozymes A/S (OTCMKTS:NVZMY) gapped down prior to trading on Friday. The stock had previously closed at $67.43, but opened at $65.29. Novozymes A/S shares last traded at $65.39, with a volume of 5,374 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Novozymes A/S Trading Down 3.9%

The company has a 50 day simple moving average of $66.63 and a two-hundred day simple moving average of $62.05. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.74. The firm has a market cap of $26.87 billion, a PE ratio of 41.03, a P/E/G ratio of 2.93 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY) last released its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%.The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.27 billion. Analysts expect that Novozymes A/S will post 2.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its holdings in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.03% of the company’s stock.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.